NCT06979271 Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis
| NCT ID | NCT06979271 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhejiang Provincial People's Hospital |
| Condition | Telitacicept |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-06-01 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with tofacitinib in the treatment of D2TRA patients
Eligibility Criteria
Inclusion Criteria: 1. Age 18-85 years 2. Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria 3. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease-improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients 4. Voluntarily provided written informed consent - Exclusion Criteria: 1. Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs) 2. Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis) 3. History of allergy/hypersensitivity to the study medications (Telitacicept or Tofacitinib) 4. Active tuberculosis or active infectious diseases requiring systemic treatment 5. Pregnancy, lactation, or refusal to use contraception during the study 6. Failure to complete the prescribed Telitacicept + Tofacitinib regimen due to: Non-adherence or Severe adverse reactions 7. Other conditions contraindicating participation per investigator judgment -
Frequently Asked Questions
Who can join the NCT06979271 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Telitacicept. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06979271 currently recruiting?
Yes, NCT06979271 is actively recruiting participants. Visit ClinicalTrials.gov or contact Zhejiang Provincial People's Hospital to inquire about joining.
Where is the NCT06979271 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06979271 clinical trial?
NCT06979271 is sponsored by Zhejiang Provincial People's Hospital. The trial plans to enroll 20 participants.